Shed Introduces Low-Dose Naltrexone (LDN) to Support Chronic Pain, Autoimmune Health, and Metabolism, Boosting Weight-Loss Solutions
SALT LAKE CITY, March 4, 2025 /PRNewswire/ -- Shed, a telehealth clinic specializing in weight loss, is excited to announce the launch of Low-Dose Naltrexone (LDN), an innovative, therapeutic solution for individuals managing chronic pain, autoimmune diseases, and metabolic health challenges. LDN works by naturally balancing the immune system, reducing inflammation, and providing pain relief, offering a much-needed alternative for patients seeking to address the root causes of their conditions.
"LDN is an exciting addition to our holistic approach to health," said Morley Baker, Founder and CEO of Shed. "With the addition of LDN, we're able to provide a comprehensive solution that not only helps patients manage weight but also supports their overall health by targeting chronic conditions that have long been difficult to treat."
What is Low-Dose Naltrexone (LDN)?
LDN is a medication that temporarily blocks opioid receptors in the body, triggering a rebound effect that stimulates endorphin production. These natural endorphins regulate the immune system, reduce inflammation, and provide pain relief. This mechanism makes LDN a promising treatment option for individuals battling autoimmune diseases, chronic pain, gastrointestinal disorders, and even mental health challenges.
Conditions Treated by LDN
LDN is being explored for its potential to help with several chronic conditions, including:
- Autoimmune Disorders – Lupus, Rheumatoid Arthritis, Hashimoto's
- Chronic Pain – Fibromyalgia, Migraines, Complex Regional Pain Syndrome (CRPS)
- Mental Health – Anxiety, Depression, OCD
- Gastrointestinal Conditions – Crohn's Disease, IBS
- Metabolic Disorders – PCOS, Hypothyroidism
"The versatility of LDN makes it an excellent option for a wide range of patients," added Baker. "By addressing inflammation and immune system regulation, LDN can provide long-term relief while also complementing weight-loss efforts."
Personalized, Flexible Treatment with LDN
To ensure optimal therapeutic results, Shed offers flex-dose LDN tablets that allow healthcare providers to tailor the dosage to each patient's unique needs. Starting at 1.5 mg, the dosage is gradually increased to achieve the best possible outcomes. This flexible approach allows Shed to offer a truly personalized treatment plan that supports each patient's journey toward better health.
Supporting Weight Loss and Metabolic Health
In addition to its anti-inflammatory benefits, LDN has shown potential in supporting weight loss by addressing the internal inflammation that often hinders metabolic function. Shed offers LDN as a complement to weight-loss medications, such as GLP-1 drugs like semaglutide, creating a holistic solution to metabolic health.
How to Access LDN Through Shed
Patients can access Low-Dose Naltrexone through Shed's easy-to-use telehealth platform. After completing an intake form, healthcare providers will assess eligibility and tailor the treatment to each patient's unique needs. This streamlined process allows patients to begin treatment with minimal delay, with medications typically arriving within 5-10 business days.
About Shed:
Shed is committed to providing innovative health and wellness solutions tailored to the individual needs of each patient. Shed offers a variety of effective treatments, including Low-Dose Naltrexone, aimed at improving health outcomes and enhancing quality of life.
For more information about Shed and how LDN can support health goals, visit www.shedrx.com.
Press Contact
Jamie Neider
(801) 520 – 5785
391060@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shed-introduces-low-dose-naltrexone-ldn-to-support-chronic-pain-autoimmune-health-and-metabolism-boosting-weight-loss-solutions-302391474.html
SOURCE Shed